Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Get more Watchlists, Portfolios, Custom Views and Chart Templates with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Ascendis Pharma ADR (ASND)

Ascendis Pharma ADR (ASND)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 12,756,726
  • Shares Outstanding, K 61,977
  • Annual Sales, $ 393,500 K
  • Annual Income, $ -409,120 K
  • EBIT $ -155 M
  • EBITDA $ -136 M
  • 60-Month Beta 0.46
  • Price/Sales 16.53
  • Price/Cash Flow N/A
  • Price/Book N/A

Options Overview Details

View History
  • Implied Volatility 50.28% (-4.22%)
  • Historical Volatility 42.56%
  • IV Percentile 66%
  • IV Rank 38.68%
  • IV High 70.31% on 08/01/25
  • IV Low 37.64% on 06/16/25
  • Expected Move (DTE 32) 26.01 (12.64%)
  • Put/Call Vol Ratio 2.89
  • Today's Volume 1,502
  • Volume Avg (30-Day) 935
  • Put/Call OI Ratio 0.27
  • Today's Open Interest 19,639
  • Open Int (30-Day) 17,380
  • Expected Range 179.82 to 231.84

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 17 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate 0.05
  • Number of Estimates 8
  • High Estimate 0.34
  • Low Estimate -0.37
  • Prior Year -0.68
  • Growth Rate Est. (year over year) +107.35%

Price Performance

See More
Period Period Low Period High Performance
1-Month
188.08 +9.44%
on 01/12/26
221.75 -7.18%
on 01/13/26
-6.28 (-2.96%)
since 12/16/25
3-Month
186.05 +10.63%
on 10/20/25
229.94 -10.49%
on 12/12/25
-1.20 (-0.58%)
since 10/16/25
52-Week
118.03 +74.39%
on 02/12/25
229.94 -10.49%
on 12/12/25
+74.21 (+56.38%)
since 01/16/25

Most Recent Stories

More News
Gamble on Huge Gains with These 3 Best Biotech Stocks to Buy for 2026

Investing in these three biotech stocks can offer investors with a high-risk profile the opportunity to generate outsized gains over the next decade.

LGND : 192.97 (-1.59%)
KNSA : 39.41 (+3.93%)
ASND : 205.83 (-4.28%)
Ascendis Pharma Provides Business and Strategic Roadmap Update at 44th Annual J.P. Morgan Healthcare Conference

COPENHAGEN, Denmark, Jan. 09, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today provided a business and strategic roadmap update, including planned 2026 key corporate milestones. Ascendis...

ASND : 205.83 (-4.28%)
Week 52 COACH Trial Topline Results Confirm Consistent and Durable Treatment Benefits in Children with Achondroplasia (ACH)

– Once-weekly TransCon ® CNP and TransCon ® hGH combination therapy showed durable growth without compromising safety or tolerability at 52 weeks – Annualized growth velocity (AGV)...

ASND : 205.83 (-4.28%)
Ascendis Pharma to Participate in the 44th Annual J.P. Morgan Healthcare Conference

COPENHAGEN, Denmark, Jan. 05, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that company executives will participate in the 44 th Annual J.P. Morgan Healthcare Conference...

ASND : 205.83 (-4.28%)
Ascendis Announces Extension of FDA Review Period for TransCon CNP (navepegritide) for Children with Achondroplasia

–  Prescription Drug User Fee Act (PDUFA) goal date extended by three months to February 28, 2026 COPENHAGEN, Denmark, Nov. 25, 2025 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today...

ASND : 205.83 (-4.28%)
Results of Pivotal ApproaCH Trial of TransCon® CNP (Navepegritide) in Children with Achondroplasia Published in JAMA Pediatrics

COPENHAGEN, Denmark, Nov. 17, 2025 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that pivotal Week 52 results from its randomized double-blind, placebo-controlled ApproaCH Trial...

ASND : 205.83 (-4.28%)
Ascendis Pharma Reports Third Quarter 2025 Financial Results

–   Q3 2025 revenue of €143.1 million for YORVIPATH ® and €50.7 million for SKYTROFA ® –   Q3 2025 operating profit of €11.0 million –   TransCon ® CNP (navepegritide)...

ASND : 205.83 (-4.28%)
New Pooled 3-Year Analysis Confirms Sustained, Clinically Meaningful Improvements in Renal Function for TransCon® PTH (Palopegteriparatide)-Treated Adults with Hypoparathyroidism

COPENHAGEN, Denmark, Nov. 07, 2025 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that a new pooled analysis showed sustained and clinically meaningful improvements in renal function...

ASND : 205.83 (-4.28%)
Ascendis Pharma to Report Third Quarter 2025 Financial Results and Provide Business Update on November 12, 2025

COPENHAGEN, Denmark, Nov. 05, 2025 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced it plans to report third quarter 2025 financial results and provide a business update on Wednesday,...

ASND : 205.83 (-4.28%)
3-Year Renal Data in Adults with Hypoparathyroidism Treated with TransCon® PTH (Palopegteriparatide) to Be Shared at Kidney Week 2025

COPENHAGEN, Denmark, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that its data showing sustained improvements in renal function, continued normalization of urine...

ASND : 205.83 (-4.28%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Buy with a Weakest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

Relative Strength just crossed below 50%. The market is indicating support for a bearish trend.

See More Share

Business Summary

Ascendis Pharma A/S is a biopharmaceutical company. The company's product pipeline consist of TransCon Human Growth Hormone, TransCon Treprostinil, TransCon Insulin, TransCon Peptide and TransCon Ranibizumab, which are in different clinical stage, for the treatments of hormone deficiency, endocrinology,...

See More

Key Turning Points

3rd Resistance Point 224.86
2nd Resistance Point 220.93
1st Resistance Point 213.38
Last Price 205.83
1st Support Level 201.90
2nd Support Level 197.97
3rd Support Level 190.42

See More

52-Week High 229.94
Last Price 205.83
Fibonacci 61.8% 187.19
Fibonacci 50% 173.99
Fibonacci 38.2% 160.78
52-Week Low 118.03

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar